Literature DB >> 22688471

Multidrug-resistant Acinetobacter baumannii infection in children.

Maia De Luca1, Giulia Angelino, Francesca Ippolita Calò Carducci, Alessandra Martino, Stefania Bernardi, Paola Bernaschi, Michaela Carletti, Patrizia D'Argenio, Paolo Palma.   

Abstract

Acinetobacter baumannii is a Gram-negative coccobacillus causing serious nosocomial infections. The recent emergence of strains of bacteria, which are resistant to common antibiotics, has made the treatment of these infections increasingly complex. We report the case of a young patient affected by AIDS, who suffered brain toxoplasmosis and sepsis due to multidrug-resistant A baumannii. This bacterial infection was successfully treated with colistin and tigecycline. In addition, we review recent literature on this topic, from the year 2000 to date.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22688471      PMCID: PMC3158346          DOI: 10.1136/bcr.02.2011.3807

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.

Authors:  M E Jiménez-Mejías; C Pichardo-Guerrero; F J Márquez-Rivas; D Martín-Lozano; T Prados; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-19       Impact factor: 3.267

2.  Ventilator-associated pneumonia with Col-S strains: a successful comeback of colistin!

Authors:  C Mukhopadhyay; S Krishna; K E Vandana; A Shenoy; I Bairy
Journal:  Braz J Infect Dis       Date:  2008-10       Impact factor: 1.949

3.  Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review.

Authors:  John Ng; Iain B Gosbell; John A Kelly; Michael J Boyle; John K Ferguson
Journal:  J Antimicrob Chemother       Date:  2006-08-17       Impact factor: 5.790

4.  Colistin administration to pediatric and neonatal patients.

Authors:  Elias Iosifidis; Charalampos Antachopoulos; Maria Ioannidou; Magda Mitroudi; Maria Sdougka; Vassiliki Drossou-Agakidou; Maria Tsivitanidou; Emmanuel Roilides
Journal:  Eur J Pediatr       Date:  2010-01-30       Impact factor: 3.183

Review 5.  Drug treatment for multidrug-resistant Acinetobacter baumannii infections.

Authors:  Matteo Bassetti; Elda Righi; Silvano Esposito; Nicola Petrosillo; Laura Nicolini
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

6.  Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.

Authors:  M Bassetti; E Repetto; E Righi; S Boni; M Diverio; M P Molinari; M Mussap; S Artioli; F Ansaldi; P Durando; G Orengo; F Bobbio Pallavicini; C Viscoli
Journal:  J Antimicrob Chemother       Date:  2008-01-03       Impact factor: 5.790

7.  Community-acquired Acinetobacter baumannii meningitis in a previously healthy 14-month-old boy.

Authors:  Takao Ozaki; Naoko Nishimura; Yasuko Arakawa; Michio Suzuki; Atsushi Narita; Yasuto Yamamoto; Norio Koyama; Kazumasa Nakane; Naoko Yasuda; Keiji Funahashi
Journal:  J Infect Chemother       Date:  2009-10-24       Impact factor: 2.211

8.  Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.

Authors:  Matthew E Falagas; Georgia Sideri; Evridiki K Vouloumanou; John H Papadatos; Dimitris A Kafetzis
Journal:  Pediatr Infect Dis J       Date:  2009-02       Impact factor: 2.129

9.  Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin.

Authors:  N Dalgic; Y Ceylan; M Sancar; L Telhan; I Kafadar; H Cavusoglu; O Ceylan; O Hasim
Journal:  Ann Trop Paediatr       Date:  2009-06

10.  In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.

Authors:  Luigi Principe; Silvia D'Arezzo; Alessandro Capone; Nicola Petrosillo; Paolo Visca
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-05-21       Impact factor: 3.944

View more
  3 in total

1.  Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.

Authors:  Sue C Kehl; Michael J Dowzicky
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

2.  Tigecycline treatment in a liver transplant infant with carbapenem-resistant Escherichia coli infection: Case report.

Authors:  Mei Yang; Hengmiao Gao; Xiaoling Wang; Suyun Qian
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials.

Authors:  Hal Tucker; Michele Wible; Ashesh Gandhi; Alvaro Quintana
Journal:  Infect Drug Resist       Date:  2017-11-03       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.